Accredo
Privacy |  HIPAA |  Terms of use |  Medco |  Contact us
   
Patients Healthcare professionals Health plans & payor clients Manufacturers Careers About Accredo
 
 
 

Patients

Getting started with Accredo
Our services
Search drug therapies
Therapy management
Hunter Syndrome (MPS II)  - overview

Hunter Syndrome (MPS II) - overview

Overview | FAQs | Lysosomal storage disorders

Hunter syndrome is a genetic disorder that inhibits the body’s ability to process glycosaminoglycans (GAG). Otherwise known as mucopolysaccharidosis II (MPS II), it occurs mainly in males. Though rare, it is a serious, life-altering condition with overt manifestations, such as distinct facial features, a large head, and an enlarged abdomen. Hearing loss, thickening of the heart valves, sleep apnea, and enlargement of the liver or spleen are also common. Mobility may be impaired. The symptoms can be unique to the individual, and the rate of progression varies widely.

Standard treatment is with Elaprase®.


Elaprase is a trademark of Shire Human Genetic Therapies, Inc.

 
 
 

Quick links

Search Search drug therapies
Doctor Referral Doctor referral forms
Patient Authorization Patient authorization form
Contact Us Contact us